Company intelligence / Profile preview

InCardia

California, United States

Ownership: Private
Development stage: Preclinical

Overview

InCarda is developing an inhaled therapy for acute episodes of paroxysmal atrial fibrillation. Their lead product, InRhythm, delivers flecainide directly to the heart via the lungs to rapidly restore normal sinus rhythm. The approach leverages approved drugs in a novel dosing paradigm and aims for rapid effect with reduced systemic exposure. The company is currently conducting clinical trials but has not yet reached commercialization.

Therapeutic areas: Cardiovascular
Modalities: Small molecules (specifically, repurposed antiarrhythmic agents delivered via inhalation)
Industry: Biotech

Beyond the preview

Go deeper on InCardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InCardia.

Explore the full profile